"Psychological assessments are essential in the management of myasthenia gravis, as the condition is frequently associated ...

Early diagnosis and treatment of generalized myasthenia gravis (MG) are important to achieve symptomatic control and limit ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States ...

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...

NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA ...

Myasthenia gravis (MG) is a rare ... They found that JYBP significantly improved symptoms and reduced disease severity. Notably, high-dose JYBP produced effects comparable to those of prednisone ...

The Company continues to progress its Phase 2b clinical study in generalized myasthenia gravis ... ClC-1 inhibition in improving symptoms for neuromuscular diseases. In the poster presentations ...

Joe’s symptoms were mild during the summer ... in communication between nerves and muscles. “Myasthenia gravis is considered a rare disease with a prevalence of approximately 100–350 ...

Supported by findings detailed in poster presentations, these results confirm the translational potential of ClC-1 inhibition in improving symptoms for neuromuscular diseases. In the poster ...

June is Myasthenia Gravis Awareness month. We are trying to raise awareness through various activities. One such activity is ...